<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PACLITAXEL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PACLITAXEL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only)</span>,
                <span class="indication">Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only)</span>,
                <span class="indication">Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only)</span>,
                <span class="indication">Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only)</span>,
                <span class="indication">Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only)</span>,
                <span class="indication">Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only)</span>,
                <span class="indication">First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only)</span>,
                <span class="indication">Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only)</span>,
                <span class="indication">In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature or local protocols).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Paclitaxel is a member of the taxane group of drugs.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (toxicity in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in severe impairment.</p>
            </section>
      </section>



      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Arrhythmia, arthralgia, febrile neutropenia, gastro-intestinal disorders, myalgia, peripheral neuropathy, sensory neuropathy, tachycardia,
              </p>
              <p>
                <strong>rare:</strong> Bradycardia, cardiac arrest, congestive heart failure, left ventricular dysfunction,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, arrhythmias (nearly always asymptomatic), asymptomatic hypotension, bone-marrow suppression, bradycardia, cardiac conduction defects, extravasation, hypersensitivity reactions, hyperuricaemia, muscle pain, myelosuppression, nausea, neutropenia, oral mucositis, pneumonitis, Stevens-Johnson syndrome, thromboembolism, toxic epidermal necrolysis, tumour lysis syndrome, vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Hypersensitivity reactions</h3>
              <p>Routine premedication with a corticosteroid, an antihistamine and a histamine H<sub>2</sub>-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA55</h3>
              <p outputclass="title">Paclitaxel for ovarian cancer (January 2003)</p> <p> <i>Either</i> paclitaxel in combination with a platinum compound (cisplatin or carboplatin) <i>or</i> a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).</p><xref format="html" href="http://www.nice.org.uk/TA55">www.nice.org.uk/TA55</xref>
                <a href="http://www.nice.org.uk/TA55" target="_blank">www.nice.org.uk/TA55</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA91</h3>
              <p outputclass="title">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p> <p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.</p> <p>Paclitaxel alone is an options for advanced ovarian cancer in patients who are allergic to platinum compounds.</p><xref format="html" href="http://www.nice.org.uk/TA91">www.nice.org.uk/TA91</xref>
                <a href="http://www.nice.org.uk/TA91" target="_blank">www.nice.org.uk/TA91</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA108</h3>
              <p outputclass="title">Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)</p> <p>Paclitaxel, within its licensed indication, is <b>not</b> recommended for the adjuvant treatment of women with early node-positive breast cancer.</p><xref format="html" href="http://www.nice.org.uk/TA108">www.nice.org.uk/TA108</xref>
                <a href="http://www.nice.org.uk/TA108" target="_blank">www.nice.org.uk/TA108</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Avoid in <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            consult product literature
          </li>
          <li>
            patients aged over 75 years with metastatic adenocarcinoma of the pancreas
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to anthracyclines.</p><p>Patients should be monitored for signs and symptoms of pneumonitis and sepsis.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.</p><p>Prescribers should specify the brand to be dispensed.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PACLITAXEL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75513"><a href="../medicinalForm/PHP75513.html" data-target="#PHP75513" data-action="load">Solution for infusion</a></div>
            <div id="PHP75519"><a href="../medicinalForm/PHP75519.html" data-target="#PHP75519" data-action="load">Powder for suspension for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
